Radiation boosts immunotherapy in Tough-to-Treat lymphoma
NCT ID NCT06867536
First seen May 16, 2026 · Last updated May 20, 2026 · Updated 1 time
Summary
This study tests whether adding a short course of radiation to the drug glofitamab can improve outcomes for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to treatment, especially when the cancer is large. About 40 adults aged 18-75 will receive both treatments. The goal is to see if the combination leads to more complete remissions than glofitamab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.